GABELLI & Co INVESTMENT ADVISERS INC. Buys Shares of 33,300 Pfizer Inc. (NYSE:PFE)

GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 33,300 shares of the biopharmaceutical company's stock, valued at approximately $883,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer during the 4th quarter worth $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer during the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC purchased a new position in shares of Pfizer during the 4th quarter worth approximately $31,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. UBS Group reduced their target price on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $31.07.

Pfizer Stock Up 0.4 %

Shares of NYSE:PFE traded up $0.09 during midday trading on Friday, hitting $22.13. 53,854,504 shares of the company's stock traded hands, compared to its average volume of 40,477,639. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a market cap of $125.50 billion, a PE ratio of 15.69, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm's fifty day moving average price is $24.88 and its two-hundred day moving average price is $26.19.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the prior year, the business earned $0.10 EPS. Pfizer's quarterly revenue was up 24.7% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.